No abstract available.
Cholesterol ; Cholesterol, LDL ; Humans ; Lipoproteins

The plasma cholesterol, TG,LDG,HDL of 101 Korean hypertensive patients were measured to compare with plasma cholesterol, TG,LDL,HDL level of healthy people(control group). The plasma cholesterol level in hypertensive patients was 189.6+/-39.5mg% and was 188.7+/-33.7mg% in healthy people(P>0.5). The plasma TG level in hypertensive patients was 200.5+/-154.2mg% and was 116.1+/-32.4mg% in healthy people(P<0.05). The plasma HDL level in hypertensive patients was 44.6+/-15.5mg% and was 45.1+/-9.8mg% in healthy people(P>0.05). The plasma LDL level in hypertensive patients was 119.0+/-68.6mg% and was 98.1+/-53.4mg% in healthy people(P>0.05). The serum level of the total cholesterol, HDL and LDL cholesterol in the hypertensive patients group were not significantly different from the control group, but the serum level of the TG was significantly increased in the patients group. We thought that this difference of plasma TG level is due to exogenous TG in hypertensive patient group but further evalution in properties of TG is required.
Cholesterol ; Cholesterol, HDL ; Cholesterol, LDL ; Humans ; Plasma

OBJECTIVES: The purpose of this study was to examine the effects of Koryo Hand Therapy(KHT) on menopausal symptoms and lipid levels in middle-aged women. METHODS: The design of this study was a nonequivalent control-group pretest-posttest design. There were 32 subjects, 40-60 years of age, and assigned to two group. There were 16 members in the experimental group and 16 members in the control group. KHT was applied three times a week, for a total of 8weeks to the experimental group. The instruments used in this study to measure the effects of KHT were the menopausal symptoms scale and clinical laboratory testing(Blood Lipid Levels). Data was analyzed by Fisher's Exact Test, Mann-Whitney U-test, and ANCOVA, using SPSS/Win PC 13.0. RESULTS: There was a statistically significant decrease in the menopausal symptoms, and levels of the total cholesterol and LDL cholesterol in the experimental group compared to the control group. CONCLUSIONS: KHT was effective in decreasing menopausal symptoms in middle-aged women. Therefore KHT is recommended as a nursing intervention strategy for middle-aged women.
Cholesterol ; Cholesterol, LDL ; Female ; Hand* ; Humans ; Nursing

No abstract available.
Cholesterol, LDL ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors

OBJECTIVE: To investigate the effects of hormone therapy (HT) on high-sensitivity C-reactive protein (hs-CRP) in surgically menopaused women. METHODS: In this study, 156 healthy women were enrolled. After surgical menopause, 28 women were receiving HT and 32 women were not for 3 months, 28 women were receiving and 32 women were not for 1 year. Control group included 36 healthy premenopausal women not receiving HT. The effect of HT on plasma levels of hs-CRP and lipids were investigated. RESULTS: Mean hs-CRP concentrations were significantly higher in surgically menopaused women receiving HT than premenopausal women (premenopausal: 0.069+/-0.080 mg/dL, HT for 3 months: 0.095+/-0.079 mg/dL, HT for 1 year: 0.159+/-0.313 mg/dL, p<0.05). Mean hs-CRP concentrations were also higher in surgically menopaused women not receiving HT than premenopausal women (premenopausal: 0.069+/-0.080 mg/dL, 3 months after surgical menopause: 0.108+/-0.215 mg/dL, 1 year after surgical menopause: 0.081+/-0.146 mg/dL, p>0.05). There was no statistically significant difference between receiving HT group and not receiving HT group in 3 months and 1 year after surgical menopause. Total cholesterol and LDL cholesterol were significantly lower in surgically menopaused women receiving HT than not receiving HT for 3 months and 1 year (total cholesterol; 191.3+/-44.7 in HT group, 227.1+/-24.5 in no HT group for 3 months after surgical menopause: 191.9+/-29.4 in HT group, 218.2+/-34.4 in no HT group for 1 year after surgical menopause, LDL cholesterol; 117.5+/-25.7 in HT group, 129.1+/-22.5 in no HT group for 3 months after surgical menopause: 120.6+/-26.2 in HT group, 136.6+/-32.1 in no HT group for 1 year after menopause). CONCLUSION: hs-CRP was increased in surgically menopaused women than premenopausal women, however, there was no significant changes in hs-CRP between HT group and no HT group for 3 months and 1 year.
C-Reactive Protein ; Cholesterol ; Cholesterol, LDL ; Female ; Humans ; Menopause ; Plasma

A new hypolipidemic drug, pravastatin, hydroxymethylglutaryl coenzyme A reductase inhibitor was administered to 33 patients with primary hyperlipidemia, 10mg daily for 8 weeks and sequential changes of lipid profile were analysed as follows. 1) Mean value at baseline period of total cholesterol, triglyceride, high and low density lipoprotein cholesterol were 260, 220, 51 and 163mg/dl respectively. 2) Total cholesterol showed 21% decrease at the end of 8 weeks and that of LDL-cholesterol were 30%. 3) Triglyceride decreased 16% at the end of 8 weeks and increment of HDL-cholesterol was 8% at the end of 8 weeks. 4) No serious side reactions were observed except one patient, who showed generalized skin rash which last 3 days and did not prevent further medication. In conclusion, pravastatin is a safe and useful hypolipidemic agent for the patient with primary hyperlipidemia.
Cholesterol ; Cholesterol, LDL ; Coenzyme A ; Exanthema ; Humans ; Hyperlipidemias* ; Oxidoreductases ; Pravastatin* ; Triglycerides

BACKGROUND: Our objective was to evaluate the accuracy of cardiovascular disease (CVD) risk score classification by direct LDL cholesterol (dLDL-C), calculated LDL cholesterol (cLDL-C), and non-HDL cholesterol (non-HDL-C) compared to classification by reference measurement procedures (RMPs) performed at the CDC. METHODS: Weexamined 175 individuals, including 138 with CVD or conditions that may affect LDL-C measurement. dLDL-C measurements were performed using Denka, Kyowa, Sekisui, Serotec, Sysmex, UMA, and Wako reagents. cLDL-C was calculated by the Friedewald equation, using each manufacturer's direct HDL-C assay measurements, and total cholesterol and triglyceride measurements by Roche and Siemens (Advia) assays, respectively. RESULTS: For participants with triglycerides <2.26 mmol/L (<200 mg/dL), the overall misclassification rate for the CVD risk score ranged from 5% to 17% for cLDL-C methods and 8% to 26% for dLDL-C methods when compared to the RMP. Only Wako dLDL-C had fewer misclassifications than its corresponding cLDL-C method (8% vs 17%; P<0.05). Non-HDL-C assays misclassified fewer patients than dLDL-C for 4 of 8 methods (P<0.05). For participants with triglycerides > or =2.26 mmol/L (> or =200 mg/dL) and <4.52 mmol/L (<400 mg/dL), dLDL-C methods, in general, performed better than cLDL-C methods, and non-HDL-C methods showed better correspondence to the RMP for CVD risk score than either dLDL-C or cLDL-C methods. CONCLUSIONS: Except for hypertriglyceridemic individuals, 7 of 8 dLDL-C methods failed to show improved CVD risk score classification over the corresponding cLDL-C methods. Non-HDL-C showed overall the best concordance with the RMP for CVD risk score classification of both normal and hypertriglyceridemic individuals.
Cardiovascular Diseases ; Cholesterol ; Cholesterol, LDL ; Humans ; Indicators and Reagents ; Triglycerides

10 Patients with primary hypercholesterolemia were treated for 12 weeks with lovastation(20mg t.i.d). Lovastatin reduced mean total and low density lipoprotein cholesterol by 43% and 57% respectively(p<0.001). High density lipoprotein cholesterol and triglyceride levels were unchanged by the drug. Adverse effects attributable to lovastatin were not observed. Thus lovastatin is considered as an effective lipid lowering agent for the treatment of primary moderate hypercholesterolemia.
Cholesterol, HDL ; Cholesterol, LDL ; Humans ; Hypercholesterolemia* ; Lovastatin* ; Triglycerides

To evaluate the efficacy and safety of lovastatin, new hypolipidemic agent of HMG-CoA reductase inhibitor, we administered lovastatin 40mg to 80mg once daily for 12 weeks in 20 patients(7 males, 13 females) with primary hypercholesterolemia, and observed the sequential chamges of the lipid profile every 4 weeks. The results are as follows ; 1) The seurm total cholesterol was reduced significantly by 31% from 321+/-36mg% to 210+/-26mg%(p<0.05). 2) The serum triglycerides was significantly reduced from 321+/-168mg% to 228+/-74mg% by 29%(p<0.05). 3) The low density lipoprotein cholesterol was reduced significantly from 177+/-36mg% to 120+/-22mg% by 32%(p<0.05). 4) The total lipid, high density lipoprotein cholesterol and very low density lipoprotein cholesterol were also reduced significantly. 5) The ratio between total cholesterol and high density lipoprotein cholesterol, low density lipoprotein cholesterol and high density lipoprotein cholesterol did not change after lovastatin therapy. 6) There was no adverse reaction due to lovastatin therapy during 12 weeks of therapy. These results suggested that lovastatin is a effective and safe now hypolipidemic agent and is a convenient HMG-CoA reductase inhibitor for clinical use.
Cholesterol ; Cholesterol, HDL ; Cholesterol, LDL ; Cholesterol, VLDL ; Humans ; Hypercholesterolemia* ; Lovastatin* ; Male ; Oxidoreductases ; Triglycerides

PURPOSE: The need for continuing Growth Hormone(GH) replacement after adolescence in patients with childhood-onset GH deficiency has been recognized. The purpose of this study was to evaluate the abnormalities of lipid profiles in young adults with childhood-onset hypopituitarism who discontinued GH therapy after the completion of height growth. METHODS: Nine male patients(mean age:22.4+/-3.3 years) with childhood-onset hypopituiatarism in whom GH treatment had been discontinued after final height was achieved were included. Their body mass index(BMI) and serum levels of total cholesterol, triglyceride(TG), high-density lipoprotein(HDL) cholesterol, and low-density lipoprotein(LDL) cholesterol were measured. The relationships of duration after GH discontinuation, age, and BMI to lipid profiles were anaylzed. RESULTS: BMI increased significantly from 21.8+/-1.9 kg/m2 before GH discontinuation to 23.0+/-3.0 kg/m2 after GH discontinuation(P<0.05). Serum levels of total cholesterol, TG, HDL cholesterol, and LDL cholesterol were 217.3+/-33.4, 237.8+/-128.2, 42.1+/-7.1, and 127.4+/-27.2 mg/dL, respectively, 3.1+/-2.0 years after GH discontinuation. Percentage of patients who had total cholesterol > or = 200 mg/dL, TG > or = 150 mg/ dL, LDL cholesterol > or = 140 mg/dL, and HDL cholesterol < or = 40 mg/dL were 77.8%, 88.9%, 44.4%, and 33.3%, respectively. All subjects had some abnormalities of lipid profiles. A significant positive correlation was found between duration after GH discontinuation and serum levels of total cholesterol and TG(r=0.84, P<0.01; r=0.83, P<0.01). A significant positive correlation was also found between age and serum levels of total cholesterol and TG(r=0.86, P<0.01; r=0.81, P<0.01). There were no correlations between BMI and serum lipid levels. CONCLUSION: Most of young adult patients with childhood-onset hypopituitarism had abnormal lipid profiles by 1-5 years after discontinuation of GH treatment. These data suggest that continuous GH treatment after completion of height growth is necessary.
Adolescent ; Adult* ; Cholesterol ; Cholesterol, HDL ; Cholesterol, LDL ; Growth Hormone* ; Humans ; Hypopituitarism* ; Male ; Young Adult